Fluorouracil News and Research

RSS
Fluorouracil is a drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite. Also called 5-fluorouracil and 5-FU.
Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

FDA approves Spectrum's FUSILEV Injection to treat metastatic colorectal cancer

FDA approves Spectrum's FUSILEV Injection to treat metastatic colorectal cancer

Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer

Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting

Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

EC grants marketing authorization for Taiho's Teysuno to treat gastric cancer

EC grants marketing authorization for Taiho's Teysuno to treat gastric cancer

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

Study supports DNA mismatch repair test for bowel cancer

Study supports DNA mismatch repair test for bowel cancer

Chromosomally unstable bowel cancer cells more resistant to chemotherapy treatments, targeted drugs

Chromosomally unstable bowel cancer cells more resistant to chemotherapy treatments, targeted drugs

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Study results presented at ASCO-GI reinforce value of Genomic Health's Oncotype DX Colon Cancer test

Study results presented at ASCO-GI reinforce value of Genomic Health's Oncotype DX Colon Cancer test

Positive results from nimotuzumab Phase II study for gastric cancer

Positive results from nimotuzumab Phase II study for gastric cancer

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Spectrum submits FUSILEV sNDA for treatment of colorectal cancer

Spectrum submits FUSILEV sNDA for treatment of colorectal cancer